Skip to main content Skip to office menu Skip to footer
Capital IconMinnesota Legislature
Skip Navigation Links
  • LRL Home
    • >
  • Mandate Search
    • >
  • Mandate Detail

    • Mandate Details

    Description: Evaluation of the registration fee on drug manufacturers, and whether the registration fee and the increased licensure fees have reduced the number of opiate prescriptions issued in 2021, 2022, and 2023, or affected the availability of opiates for treating chronic or intractable pain.
    Law: 2019 Minn. Laws Chap. 63 Art. 1 Sec. 5 Subd. 4
    Statute: 151.066 Subd. 4
    Agency(ies)/Supplier(s): Minn. Board of Pharmacy
    Due Date: 03/01/2024
    Frequency: One time
    Subjects: Health Care - Pharmaceuticals
    Committee/Agency Jurisdiction: Health and Human Services Policy and Finance

    Item(s) Received

    TitlePublisher(s)Publication DateCoverageDate ReceivedReport LinkCall #
    Report to the Legislature: Evaluation of Opiate Product Registration Fee & Increased Licensure Fees on Opiate Prescribing and Treating Chronic or Intractable Pain Minn. Board of Pharmacy February 28, 2024Calendar years 2021, 2022, and 202303/01/2024 24-0407.pdf
         		RC568.O45 F74 2024